148 related articles for article (PubMed ID: 37555380)
1. Risk of cancer with immunosuppressants compared to immunomodulators in multiple sclerosis: A nested case-control study within the French nationwide claims database.
Bosco-Lévy P; Boutmy E; Guiard E; Foch C; Lassalle R; Favary C; Sabidó M; Blin P
Pharmacoepidemiol Drug Saf; 2023 Dec; 32(12):1421-1430. PubMed ID: 37555380
[TBL] [Abstract][Full Text] [Related]
2. Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study.
Confavreux C; Saddier P; Grimaud J; Moreau T; Adeleine P; Aimard G
Neurology; 1996 Jun; 46(6):1607-12. PubMed ID: 8649558
[TBL] [Abstract][Full Text] [Related]
3. Risk of cancer among Finnish multiple sclerosis patients.
Hongell K; Kurki S; Sumelahti ML; Soilu-Hänninen M
Mult Scler Relat Disord; 2019 Oct; 35():221-227. PubMed ID: 31404761
[TBL] [Abstract][Full Text] [Related]
4. [CARIMS (Cancer Risk In Multiple Sclerosis) project: impact of long-term treatment].
Lebrun C; Debouverie M; Vermersch P; Clavelou P; Rumbach L; de Seze J; Defer G; Berthier F;
Rev Neurol (Paris); 2007 Jan; 163(1):38-46. PubMed ID: 17304171
[TBL] [Abstract][Full Text] [Related]
5. Cancer and multiple sclerosis in the era of disease-modifying treatments.
Lebrun C; Vermersch P; Brassat D; Defer G; Rumbach L; Clavelou P; Debouverie M; de Seze J; Wiertlevsky S; Heinzlef O; Tourbah A; Fromont A; Frenay M
J Neurol; 2011 Jul; 258(7):1304-11. PubMed ID: 21293872
[TBL] [Abstract][Full Text] [Related]
6. Comparative effectiveness of dimethyl fumarate in multiple sclerosis.
Bosco-Lévy P; Debouverie M; Brochet B; Guillemin F; Louapre C; Maillart E; Heinzlef O; Lignot S; Diez P; Abouelfath A; Lassalle R; Blin P; Droz-Perroteau C
Br J Clin Pharmacol; 2022 Mar; 88(3):1268-1278. PubMed ID: 34505304
[TBL] [Abstract][Full Text] [Related]
7. Assessment of cancer risk with β-interferon treatment for multiple sclerosis.
Kingwell E; Evans C; Zhu F; Oger J; Hashimoto S; Tremlett H
J Neurol Neurosurg Psychiatry; 2014 Oct; 85(10):1096-102. PubMed ID: 24594506
[TBL] [Abstract][Full Text] [Related]
8. Season of infectious mononucleosis as a risk factor for multiple sclerosis: A UK primary care case-control study.
Downham C; Visser E; Vickers M; Counsell C
Mult Scler Relat Disord; 2017 Oct; 17():103-106. PubMed ID: 29055437
[TBL] [Abstract][Full Text] [Related]
9. Incidence and risk of cancer among multiple sclerosis patients: A matched population-based cohort study.
Bosco-Lévy P; Foch C; Grelaud A; Sabidó M; Lacueille C; Jové J; Boutmy E; Blin P
Eur J Neurol; 2022 Apr; 29(4):1091-1099. PubMed ID: 34936169
[TBL] [Abstract][Full Text] [Related]
10. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.
Filippini G; Del Giovane C; Vacchi L; D'Amico R; Di Pietrantonj C; Beecher D; Salanti G
Cochrane Database Syst Rev; 2013 Jun; (6):CD008933. PubMed ID: 23744561
[TBL] [Abstract][Full Text] [Related]
11. Ocrelizumab in highly disabled progressive multiple sclerosis patients.
Houtchens M; Howard D
Mult Scler Relat Disord; 2024 Feb; 82():105345. PubMed ID: 38181693
[TBL] [Abstract][Full Text] [Related]
12. Decreased risk of cancer in multiple sclerosis patients and analysis of the effect of disease modifying therapies on cancer risk.
Gaindh D; Kavak KS; Teter B; Vaughn CB; Cookfair D; Hahn T; Weinstock-Guttman B;
J Neurol Sci; 2016 Nov; 370():13-17. PubMed ID: 27772741
[TBL] [Abstract][Full Text] [Related]
13. Cumulative immunosuppressant exposure is associated with diversified cancer risk among 14 832 patients with systemic lupus erythematosus: a nested case-control study.
Hsu CY; Lin MS; Su YJ; Cheng TT; Lin YS; Chen YC; Chiu WC; Chen TH
Rheumatology (Oxford); 2017 Apr; 56(4):620-628. PubMed ID: 28039419
[TBL] [Abstract][Full Text] [Related]
14. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
[TBL] [Abstract][Full Text] [Related]
15. Cancer Risk in Patients with Multiple Sclerosis: Potential Impact of Disease-Modifying Drugs.
Lebrun C; Rocher F
CNS Drugs; 2018 Oct; 32(10):939-949. PubMed ID: 30143945
[TBL] [Abstract][Full Text] [Related]
16. Association between multiple sclerosis, cancer risk, and immunosuppressant treatment: a cohort study.
Ragonese P; Aridon P; Vazzoler G; Mazzola MA; Lo Re V; Lo Re M; Realmuto S; Alessi S; D'Amelio M; Savettieri G; Salemi G
BMC Neurol; 2017 Aug; 17(1):155. PubMed ID: 28789625
[TBL] [Abstract][Full Text] [Related]
17. Cumulative exposure to biological therapy and risk of cancer in patients with psoriasis: a meta-analysis of Psonet studies from Israel, Italy, Spain, the U.K. and Republic of Ireland.
Garcia-Doval I; Descalzo MA; Mason KJ; Cohen AD; Ormerod AD; Gómez-García FJ; Cazzaniga S; Feldhamer I; Ali H; Herrera-Acosta E; Griffiths CEM; Stern RS; Naldi L;
Br J Dermatol; 2018 Oct; 179(4):863-871. PubMed ID: 29723914
[TBL] [Abstract][Full Text] [Related]
18. Infectious exposure, antibiotic use, and multiple sclerosis: A population-based incident case-control study.
Abdollahpour I; Nedjat S; Mansournia MA; Eckert S; Weinstock-Guttman B
Acta Neurol Scand; 2018 Oct; 138(4):308-314. PubMed ID: 29740825
[TBL] [Abstract][Full Text] [Related]
19. SARS-CoV-2 pandemic as a model to assess the relationship between intercurrent viral infections and disease activity in Multiple Sclerosis: A propensity score matched case-control study.
Vercellino M; Bosa C; Alteno A; Muccio F; Marasciulo S; Garelli P; Cavalla P
Mult Scler Relat Disord; 2023 Jun; 74():104715. PubMed ID: 37058763
[TBL] [Abstract][Full Text] [Related]
20. Cancer Risk in Inflammatory Bowel Disease: A 6-Year Prospective Multicenter Nested Case-Control IG-IBD Study.
Biancone L; Armuzzi A; Scribano ML; Castiglione F; D'Incà R; Orlando A; Papi C; Daperno M; Vecchi M; Riegler G; Fries W; Alvisi P; Meucci G; Mocciaro F; Rogai F; Festa S; Guidi L; Testa A; Spina L; Renna S; Viola A; Patturelli M; Di Mitri R; Frankovic I; Calabrese E; Petruzziello C; De Cristofaro E; Sena G; Ruffa A; Neri B; Rossi A
Inflamm Bowel Dis; 2020 Feb; 26(3):450-459. PubMed ID: 31498388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
